Renal Glucose Handling Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
Renal Glucose Handling Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
复制标题
DOI：
10.2337/dc12-1503
复制
发表时间：
2013-05-01
期刊：
影响因子：
16.2
通讯作者：
Kadokura, Takeshi
中科院分区：
文献类型：
--
作者：
Ferrannini, Ele;Veltkamp, Stephan A.;Kadokura, Takeshi
利格列汀是一种钠-葡萄糖协同转运蛋白2抑制剂，可刺激2型糖尿病（T2 DM）患者的糖尿并降低血糖。本研究的目的是评估伊格列净在肾功能受损的2型糖尿病患者中的药效学。研究设计和方法-在8名非糖尿病受试者和57名2型糖尿病患者中，在单剂量伊格列净之前和之后测量糖尿（年龄62 +/- 9岁，空腹血糖133 +/- 39 mg/dL，平均值+/- SD），肾功能正常（评估为估计的肾小球滤过率[eGFR]）（eGFR（1）>= 90 mL . min（-1）。1.73 m（-2））、轻度（eGFR（2）≥ 60至= 30至
OBJECTIVE-Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, stimulates glycosuria and lowers glycemia in patients with type 2 diabetes (T2DM). The objective of this study was to assess the pharmacodynamics of ipragliflozin in T2DM patients with impaired renal function.RESEARCH DESIGN AND METHODS-Glycosuria was measured before and after a single ipragliflozin dose in 8 nondiabetic subjects and 57 T2DM patients (age 62 +/- 9 years, fasting glucose 133 +/- 39 mg/dL, mean +/- SD) with normal renal function (assessed as the estimated glomerular filtration rate [eGFR]) (eGFR(1) >= 90 mL . min(-1) . 1.73 m(-2)), mild (eGFR(2) >= 60 to = 30 to